{"content":"<li class=\"n-box-item date-title\" data-end=\"1506052799\" data-start=\"1505966400\" data-txt=\"Monday, December 23, 2019\">Thursday, September 21, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3297020\" data-ts=\"1506029750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297020-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a> <font color='green'>+42.3%</font>. <a href='https://seekingalpha.com/symbol/TUES' title='Tuesday Morning Corp.'>TUES</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/GKOS' title='Glaukos'>GKOS</a> <font color='green'>+2.5%</font>. <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='green'>+1.6%</font>. <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color='green'>+1.5%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a> <font color='red'>-84.0%</font>. <a href='https://seekingalpha.com/symbol/PSDO' title='Presidio'>PSDO</a> <font color='red'>-7.5%</font>. <a href='https://seekingalpha.com/symbol/STON' title='StoneMor Partners L.P.'>STON</a> <font color='red'>-2.8%</font>. <a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a> <font color='red'>-1.4%</font>. <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='red'>-1.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297020\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ASND $TUES $GKOS - After Hours Gainers / Losers https://seekingalpha.com/news/3297020-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3297020-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297011\" data-ts=\"1506026697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXN\" target=\"_blank\">TXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297011-texas-instruments-announces-6b-share-repurchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas Instruments announces $6B share repurchase</a></h4><ul><li>        Texas Instruments (NYSE:<a href='https://seekingalpha.com/symbol/TXN' title='Texas Instruments Inc.'>TXN</a>) <a href=\"https://seekingalpha.com/pr/16948222-ti-return-cash-shareholders-24-percent-dividend-increase-authorization-additional-6_0-billion\" target=\"_blank\">announces</a> board authorization of a $6B share repurchase of common stock.</li><li>               The new amount adds to the $4.6B previously authorized repurchases that remained at the end of June.&nbsp;</li><li>Texas Instruments shares are&nbsp;<font color='green'>up 1.28%&nbsp;</font>aftermarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297001-texas-instruments-declares-0_62-dividend\" target=\"_blank\">Texas Instruments declares $0.62 dividend</a> (Sept. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297011\" data-linked=\"Texas Instruments announces $6B share repurchase\" data-tweet=\"$TXN - Texas Instruments announces $6B share repurchase https://seekingalpha.com/news/3297011-texas-instruments-announces-6b-share-repurchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3297011-texas-instruments-announces-6b-share-repurchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297008\" data-ts=\"1506026646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAR-OLD\" target=\"_blank\">VSAR-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297008-versartis-lead-candidate-vrsminus-317-flunks-late-stage-study-shares-poised-for-significant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Versartis&#39; lead candidate VRS-317 flunks late-stage study; shares poised for significant drop</a></h4><ul><li>Thinly traded small cap Versartis (NASDAQ:<a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a>) is set for a tumble after <a href=\"https://seekingalpha.com/pr/16948217-versartis-announces-phase-3-velocity-trial-somavaratan-pediatric-growth-hormone-deficiency\" target=\"_blank\">reporting</a> negative results in a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02339090?term=versartis&amp;rank=5\" target=\"_blank\">VELOCITY</a>, assessing lead candidate somavaratan (VRS-317) for the treatment of pediatric growth hormone deficiency.</li><li>The study failed to achieve its primary endpoint of non-inferiority (no worse than) to Pfizer's (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) <a href=\"http://www.genotropin.com/\" target=\"_blank\">Genotropin </a>(somatatropin [rDNA origin] for injection) in the intent-to-treat population, but did demonstrate non-inferiority in the per-protocol population.</li><li>CEO Jay Shepard says, &ldquo;We are very surprised and disappointed to learn the outcome of the VELOCITY trial. Somavaratan showed height velocity in the range we had hoped, but it was not sufficient to demonstrate non-inferiority in this trial. We have done an initial analysis of the top-line data and are continuing to thoroughly review the results to gain greater insight into the trial outcome. We plan to provide a corporate update later this year. I would like to thank the investigators, pediatric GHD patients and families that participated in the VELOCITY trial.&rdquo;</li><li>Trading, currently suspended, will resume at 5:00 pm ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2613645-versartis-up-20-percent-after-fda-lifts-partial-clinical-hold-on-late-stage-stage-of-lead-product-candidate\" target=\"_blank\">Versartis up 20% after FDA lifts partial clinical hold on late stage stage of lead product candidate</a> (July 6, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297008\" data-linked=\"Versartis&#39; lead candidate VRS-317 flunks late-stage study; shares poised for significant drop\" data-tweet=\"$VSAR-OLD $VSAR-OLD $PFE - Versartis&#39; lead candidate VRS-317 flunks late-stage study; shares poised for significant drop https://seekingalpha.com/news/3297008-versartis-lead-candidate-vrsminus-317-flunks-late-stage-study-shares-poised-for-significant?source=tweet\" data-url=\"https://seekingalpha.com/news/3297008-versartis-lead-candidate-vrsminus-317-flunks-late-stage-study-shares-poised-for-significant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>167&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296997\" data-ts=\"1506025779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSAR-OLD\" target=\"_blank\">VSAR-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296997-trading-in-versartis-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading in Versartis halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Versartis (NASDAQ:<a href='https://seekingalpha.com/symbol/VSAR-OLD' title='Versartis, Inc.'>VSAR-OLD</a>) pending the release of news.</li><li>Data from a Phase 3 study assessing lead candidate VRS-317 may be the source of the news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2613645-versartis-up-20-percent-after-fda-lifts-partial-clinical-hold-on-late-stage-stage-of-lead-product-candidate\" target=\"_blank\">Versartis up 20% after FDA lifts partial clinical hold on late stage stage of lead product candidate</a> (July 6, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296997\" data-linked=\"Trading in Versartis halted pending news\" data-tweet=\"$VSAR-OLD - Trading in Versartis halted pending news https://seekingalpha.com/news/3296997-trading-in-versartis-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3296997-trading-in-versartis-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296977\" data-ts=\"1506023939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEG\" target=\"_blank\">PEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296977-psegplus-2-morgan-stanley-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PSEG +2% as Morgan Stanley upgrades</a></h4><ul>     <li>Public Service Enterprise (<a href='https://seekingalpha.com/symbol/PEG' title='Public Service Enterprise Group Inc.'>PEG</a> <font color='green'>+2.2%</font>) is higher after Morgan Stanley <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10086334/public-service-enterprise-to-finally-gets-its-props-mor\" target=\"_blank\">upgrades</a> shares to Overweight from Equal Weight with a $53 price target, believing the power company's risk-reward profile is \"skewed heavily to the upside\" given the stock's YTD underperformance vs. peers and several constructive regulatory initiatives that are pending.</li>     <li>Stanley sees PEG as a well-run company with a high growth utility and quality merchant power business, and best-in-class 9% utility growth, supported by merchant free cash flow and a robust infrastructure investment plan.</li>     <li>The firm thinks PEG's current stock price reflects very limited value for power despite its strong investment grade credit metrics, which is at an unchanged 25% free cash flow yield.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296977\" data-linked=\"PSEG +2% as Morgan Stanley upgrades\" data-tweet=\"$PEG - PSEG +2% as Morgan Stanley upgrades https://seekingalpha.com/news/3296977-psegplus-2-morgan-stanley-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3296977-psegplus-2-morgan-stanley-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296974\" data-ts=\"1506022992\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296974-anadarko-wins-praise-for-2_5b-stock-buyback-program-sharesplus-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anadarko wins praise for $2.5B stock buyback program, shares +7%</a></h4><ul>     <li>Anadarko Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+7.2%</font>) surges to the <a href=\"http://www.marketwatch.com/story/anadarkos-stock-surges-to-lead-sp-500-gainers-after-share-buyback-announcement-2017-09-21\" target=\"_blank\">top of the S&amp;P 500 leaderboard</a> following news of its <a href=\"https://seekingalpha.com/news/3296743-anadarko-petroleum-launches-2_5b-stock-buyback\" target=\"_blank\">$2.5B share buyback program</a> through the end of 2018, including plans to repurchase $1B before the end of 2017.</li><li>The buyback program is <a href=\"https://www.ft.com/content/889702cb-2c48-3e4b-9ccd-2c1b65dd031a\" target=\"_blank\">praised</a> by Drexel Hamilton analysts, who also point to APC's &ldquo;strong balance sheet,\" relatively high margins and $6B in cash, adding that the buybacks were a &ldquo;positive signal that [the company] remains focused on creating value not just through... merely drilling for growth's sake... or M&amp;A at any price.\" The firm reiterates its Buy rating and $100 price target.</li>     <li>Evercore ISI says APC's move is <a href=\"https://thefly.com/landingPageNews.php?id=2612481&amp;headline=APC-Anadarko-B-buyback-a-positive-for-EampP-stocks-says-Evercore-ISI\" target=\"_blank\">positive</a> for both fundamentals and sentiment surrounding the company and for the E&amp;P sector, and that the company is reacting to the shifting environment while showing growth will not come at any price; the firm rates APC at Outperform with a $62 target.</li>     <li>Morgan Stanley notes that APC also <a href=\"http://www.barrons.com/articles/anadarko-time-to-take-stock-1506009955\" target=\"_blank\">improved its 2018 upstream outlook</a>, and speculates that APC is re-examining whether its current guidance for long-term production growth provides strong shareholder value given current crude oil prices.</li>     <li>Stanley says APC&rsquo;s announcement is \"a harbinger for incremental capital discipline and transparency among E&amp;Ps that could both improve valuations and modestly reduce the 2018 production growth outlook.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296974\" data-linked=\"Anadarko wins praise for $2.5B stock buyback program, shares +7%\" data-tweet=\"$APC - Anadarko wins praise for $2.5B stock buyback program, shares +7% https://seekingalpha.com/news/3296974-anadarko-wins-praise-for-2_5b-stock-buyback-program-sharesplus-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3296974-anadarko-wins-praise-for-2_5b-stock-buyback-program-sharesplus-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296970\" data-ts=\"1506022791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCRX\" target=\"_blank\">OCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296970-yet-another-tiny-biotech-rocket-ocera-therapeutics-up-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yet another tiny biotech rocket; Ocera Therapeutics up 24%</a></h4><ul><li>Tiny biotechs are seemingly popping everywhere. Thinly traded nano cap Ocera Therapeutics (<a href='https://seekingalpha.com/symbol/OCRX' title='Ocera Therapeutics, Inc.'>OCRX</a> <font color='green'>+24.1%</font>) is the latest member of the club, although shares remain in a long-term downtrend.</li><li>At the end of June, it had $20.6M in quick assets and is consuming ~$6M per quarter so it's not in as much of a time crunch to raise additional capital as some others.</li><li>Its lead product candidate is Phase 3-stage <a href=\"http://www.ocerainc.com/ocr-002/\" target=\"_blank\">OCR-002</a> (ornithine phenylacetate) for the potential treatment of hepatic encephalopathy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296970\" data-linked=\"Yet another tiny biotech rocket; Ocera Therapeutics up 24%\" data-tweet=\"$OCRX - Yet another tiny biotech rocket; Ocera Therapeutics up 24% https://seekingalpha.com/news/3296970-yet-another-tiny-biotech-rocket-ocera-therapeutics-up-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3296970-yet-another-tiny-biotech-rocket-ocera-therapeutics-up-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296966\" data-ts=\"1506021392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSLP\" target=\"_blank\">MSLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296966-musclepharm-up-19-capital-raise-in-offing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MusclePharm up 19%, capital raise in the offing?</a></h4><ul><li>MusclePharm (<a href='https://seekingalpha.com/symbol/MSLP' title='MusclePharm Corp.'>OTCQB:MSLP</a> <font color='green'>+19.2%</font>) is the latest thinly traded nano cap to jump on higher volume on no particular news.</li><li>Shares are still mired in a long-term downtrend and had lost ~45% of their value since May before today's action.</li><li>The stock's behavior may presage an equity offering. At the end of June, the company only had $3.6M in the bank and operations are consuming $2M - 3M per quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3251308-musclepharm-2016-revenues-21-percent-net-loss-narrows-93-percent-restructuring-process\" target=\"_blank\">MusclePharm 2016 revenues down 21%, net loss narrows 93%; restructuring process completed; shares ease 5%</a> (March 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296966\" data-linked=\"MusclePharm up 19%, capital raise in the offing?\" data-tweet=\"$MSLP - MusclePharm up 19%, capital raise in the offing? https://seekingalpha.com/news/3296966-musclepharm-up-19-capital-raise-in-offing?source=tweet\" data-url=\"https://seekingalpha.com/news/3296966-musclepharm-up-19-capital-raise-in-offing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>251&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296961\" data-ts=\"1506020123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296961-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/GVP' title='GSE Systems, Inc'>GVP</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SPCB' title='SuperCom, Ltd.'>SPCB</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IOTS' title='Adesto Technologies'>IOTS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296961\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$VERI $GVP $IZEA - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3296961-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296961-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296959\" data-ts=\"1506018926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOL\" target=\"_blank\">GOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296959-delta-eyes-larger-stake-in-gol-linhas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delta eyes larger stake in Gol Linhas</a></h4><ul> <li>Gol Linhas (NYSE:<a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas Aéreas Inteligentes S.A.'>GOL</a>) spikes after Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a>) President Glen Hauenstein says the company is likely to increase its stake in the Latin America carrier.</li> <li>Gol <font color='green'>jumped 8%</font> in Sao Paulo trading and the U.S. ADRs are <font color='green'>5.5% higher</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3296959\" data-linked=\"Delta eyes larger stake in Gol Linhas\" data-tweet=\"$GOL $GOL $DAL - Delta eyes larger stake in Gol Linhas https://seekingalpha.com/news/3296959-delta-eyes-larger-stake-in-gol-linhas?source=tweet\" data-url=\"https://seekingalpha.com/news/3296959-delta-eyes-larger-stake-in-gol-linhas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296958\" data-ts=\"1506017403\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTE\" target=\"_blank\">PTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296958-polarityte-closes-17_75m-preferred-stock-private-placement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PolarityTE closes $17.75M preferred stock private placement</a></h4><ul>   <li>PolarityTE (COOL) has closed a private placement of <a href=\"https://seekingalpha.com/pr/16947437-polarityte-announces-closing-17_75-million-market-private-placement\" target=\"_blank\">$17.75M in preferred stock</a>.</li>    <li>The company closed that amount in Series F convertible preferred shares in an above-market private placement. The preferred stock converts into common stock at $27.50/share and a half-warrant, exercisable at $30/share.</li>    <li>Common shares today are <font color='green'>up 3.1%</font> to $26.49.</li>    <li>Cantor Fitzgerald acted as adviser.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296958\" data-linked=\"PolarityTE closes $17.75M preferred stock private placement\" data-tweet=\"$PTE - PolarityTE closes $17.75M preferred stock private placement https://seekingalpha.com/news/3296958-polarityte-closes-17_75m-preferred-stock-private-placement?source=tweet\" data-url=\"https://seekingalpha.com/news/3296958-polarityte-closes-17_75m-preferred-stock-private-placement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296957\" data-ts=\"1506016941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296957-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/TGA' title='Transglobe Energy Corp'>TGA</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/ESTE' title='Earthstone Energy, Inc.'>ESTE</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296957\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$APC $CGG-OLD $TGA - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3296957-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296957-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296954\" data-ts=\"1506016562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPRE\" target=\"_blank\">TPRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296954-hurricane-relief-for-insurance-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hurricane relief for some insurance stocks</a></h4><ul> <li>Select insurance stocks are higher after the forecast track for Hurricane Maria pushes further away from the U.S. and some estimates on Hurricanes Irma and Harvey arrive at better levels than feared.</li> <li>Notable gainers include Third Point Reinsurance (<a href='https://seekingalpha.com/symbol/TPRE' title='Third Point Reinsurance'>TPRE</a> <font color='green'>+7.3%</font>), Global Indemnity (<a href='https://seekingalpha.com/symbol/GBLI' title='Global Indemnity plc'>GBLI</a> <font color='green'>+2.5%</font>), WMIH (WMIH), Renaissance Re (<a href='https://seekingalpha.com/symbol/RNR' title='RenaissanceRe Holdings Ltd.'>RNR</a> <font color='green'>+1.4%</font>), XL Group (<a href='https://seekingalpha.com/symbol/XL' title='XL Group plc'>XL</a> <font color='green'>+1.4%</font>), Validus Holdings (<a href='https://seekingalpha.com/symbol/VR' title='Validus Holdings, Ltd.'>VR</a> <font color='green'>+1.4%</font>), Atlas Financial (<a href='https://seekingalpha.com/symbol/AFH' title='Atlas Financial Holdings'>AFH</a> <font color='green'>+1.4%</font>). and Everest Re Group (<a href='https://seekingalpha.com/symbol/RE' title='Everest Re Group Ltd.'>RE</a> <font color='green'>+1.2%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3296954\" data-linked=\"Hurricane relief for some insurance stocks\" data-tweet=\"$TPRE $TPRE $GBLI - Hurricane relief for some insurance stocks https://seekingalpha.com/news/3296954-hurricane-relief-for-insurance-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3296954-hurricane-relief-for-insurance-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296952\" data-ts=\"1506015379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTLA\" target=\"_blank\">NTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296952-intellia-up-10-on-potential-improvement-in-crispr-cas9-gene-editing-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellia up 10% on potential improvement in CRISPR/Cas9 gene-editing technology</a></h4><ul><li>Thinly traded gene editing outfit Intellia Therapeutics (<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+9.5%</font>) is up on a 40% spike in volume, albeit on turnover of only 385K shares, in apparent response to the <a href=\"https://phys.org/news/2017-09-discovery-accuracy-crispr-cas9-gene.html?utm_source=feedburner&amp;utm_medium=twitter&amp;utm_campaign=Feed:+phys/btbG+%28Phys.org+mediat_science+latest+science+and+technology+news%29\" target=\"_blank\">news </a>that scientists at UC-Berkeley and Massachusetts General Hospital have found a way to improve the precision of DNA-editing technology CRISPR/Cas9.</li><li>They have found a region within the Cas9 protein (the enzyme that does the cutting) that governs how precisely CRISPR/Cas9 hones in on the targeted DNA sequence. They have \"tweaked\" the domain to produce a \"hyper-accurate\" gene editor with the lowest level of off-target cutting achieved to date. The discovery should enable scientists to customize variants of Cas9 aimed at minimizing the chance that CRISPR/Cas9 edits DNA in the wrong place. In other words, it should contribute greatly to the efficacy and safety of gene therapies.</li><li>The much-hyped technology was tarnished a bit on reports of higher-than-expected off-target DNA editing in several research studies.</li><li>The UC-Berkeley research team is from the laboratory of Dr. Jennifer Doudna, the co-discoverer (arguably) of CRISPR/Cas9. Intellia was created to develop and commercialize the technology based on UC-Berkeley's intellectual property estate.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+7.3%</font>)(<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='green'>+0.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296952\" data-linked=\"Intellia up 10% on potential improvement in CRISPR/Cas9 gene-editing technology\" data-tweet=\"$NTLA $NTLA $EDIT - Intellia up 10% on potential improvement in CRISPR/Cas9 gene-editing technology https://seekingalpha.com/news/3296952-intellia-up-10-on-potential-improvement-in-crispr-cas9-gene-editing-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3296952-intellia-up-10-on-potential-improvement-in-crispr-cas9-gene-editing-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296949\" data-ts=\"1506013229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296949-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/TPRE' title='Third Point Reinsurance'>TPRE</a> <font color='green'>+8%</font>.<a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SVVC' title='Firsthand Technology Value Fund'>SVVC</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296949\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$MSB $TPRE $QIWI - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3296949-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296949-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296948\" data-ts=\"1506012816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLX\" target=\"_blank\">CLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296948-consumer-staples-underperform-after-dr-pepper-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer staples underperform after Dr Pepper warning</a></h4><ul> <li>Consumer staples are weak after Dr Pepper Snapple lowers its profit forecast due in part to supply issues resulting from the string of natural disasters in the Caribbean, U.S. and Mexico.</li> <li>Wells Fargo analyst Bonnie Herzog warns that similar disruptions could hit other consumer staples names such as Clorox (<a href='https://seekingalpha.com/symbol/CLX' title='The Clorox Company'>CLX</a> <font color='red'>-2%</font>), PepsiCo (<a href='https://seekingalpha.com/symbol/PEP' title='PepsiCo Inc.'>PEP</a> <font color='red'>-0.3%</font>), Kimberly-Clark (<a href='https://seekingalpha.com/symbol/KMB' title='Kimberly-Clark Corporation'>KMB</a> <font color='red'>-1.2%</font>), Church &amp; Dwight (<a href='https://seekingalpha.com/symbol/CHD' title='Church & Dwight Co Inc.'>CHD</a> <font color='red'>-1.8%</font>) and Procter &amp; Gamble (<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='red'>-1.6%</font>) (per Bloomberg).</li> <li>The list of staples stocks retreating today include Coty (<a href='https://seekingalpha.com/symbol/COTY' title='Coty Inc.'>COTY</a> <font color='red'>-3.4%</font>), Avon Products (<a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='red'>-3%</font>), Estee Lauder (<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a> <font color='red'>-1.6%</font>), Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a> <font color='red'>-1.4%</font>), Energizer (<a href='https://seekingalpha.com/symbol/ENR' title='Energizer Holdings, Inc.'>ENR</a> <font color='red'>-1%</font>) and Molson Coors (<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a> <font color='red'>-0.9%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296835-dr-pepper-trims-profit-guidance\" target=\"_blank\">Dr Pepper trims profit guidance</a> (Sept. 21)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296948\" data-linked=\"Consumer staples underperform after Dr Pepper warning\" data-tweet=\"$CLX $CLX $PEP - Consumer staples underperform after Dr Pepper warning https://seekingalpha.com/news/3296948-consumer-staples-underperform-after-dr-pepper-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3296948-consumer-staples-underperform-after-dr-pepper-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296946\" data-ts=\"1506012301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296946-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CCC-OLD' title='Calgon Carbon Corporation'>CCC-OLD</a> <font color='green'>+62%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+60%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/GVP' title='GSE Systems, Inc'>GVP</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+14%</font>. IPXL <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/IOTS' title='Adesto Technologies'>IOTS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296946\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CCC-OLD $AKTX $ARDM - Midday Gainers / Losers https://seekingalpha.com/news/3296946-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3296946-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296942\" data-ts=\"1506011214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HON\" target=\"_blank\">HON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296942-honeywell-unveil-surprise-portfolio-shakeup-deutsche-bank-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Honeywell could unveil surprise portfolio shakeup, Deutsche Bank says</a></h4><ul>     <li>Honeywell (<a href='https://seekingalpha.com/symbol/HON' title='Honeywell International, Inc.'>HON</a> <font color='green'>+1.6%</font>) is higher as Deutsche Bank <a href=\"http://thefly.com/thestreet/realmoney/index.php/HONid2612517/HON-Honeywell-could-rally-over--on-portfolio-shakeup-says-Deutsche-Bank\" target=\"_blank\">reiterates its Buy rating</a> on the stock with a $154 price target, as the firm expects news from HON's presentation of its portfolio review next month before reporting earnings on Oct. 20.</li><li>DB believes most of investors anticipate the review as a non-event, with HON likely to retain its Aerospace  business and perhaps fine-tune other parts of the portfolio, but the firm thinks the company may separate up to 30% of its profits.</li><li>If HON opts to sell or spin off of its Turbochargers unit and most of its Home and Building Technologies  businesses, the firm estimates shares could rise by 14% or more, unlocking potentially up to $20B in equity value.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296942\" data-linked=\"Honeywell could unveil surprise portfolio shakeup, Deutsche Bank says\" data-tweet=\"$HON - Honeywell could unveil surprise portfolio shakeup, Deutsche Bank says https://seekingalpha.com/news/3296942-honeywell-unveil-surprise-portfolio-shakeup-deutsche-bank-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3296942-honeywell-unveil-surprise-portfolio-shakeup-deutsche-bank-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296941\" data-ts=\"1506010836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRX\" target=\"_blank\">AMRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296941-rumor-du-jour-impax-labs-mulling-merger-amneal-pharma-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rumor du jour: Impax Labs mulling merger with Amneal Pharma; shares up 6%</a></h4><ul><li>Impax Laboratories (IPXL <font color='green'>+5.8%</font>) perks on chatter that it could be in merger talks with generic drug maker <a href=\"http://www.amneal.com/about/our-story/\" target=\"_blank\">Amneal Pharmaceuticals</a>.</li><li>In March, a FiercePharma <a href=\"http://www.fiercepharma.com/pharma/impax-weighs-m-a-options-amid-industry-wide-generics-struggles\" target=\"_blank\">article </a>implied that Impax wanted to get bigger via the M&amp;A route.</li><li>Source: Briefing.com</li><li><strong>Update</strong>: According to the <a href=\"https://www.wsj.com/articles/impax-laboratories-in-talks-to-merge-with-amneal-pharmaceuticals-1506011331\" target=\"_blank\">Wall Street Journal</a>, the companies are, indeed, in discussions on a possible combination. A deal could be announced as early as next month. A takeover could boost Impax's value north of $2B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296941\" data-linked=\"Rumor du jour: Impax Labs mulling merger with Amneal Pharma; shares up 6%\" data-tweet=\"$AMRX - Rumor du jour: Impax Labs mulling merger with Amneal Pharma; shares up 6% https://seekingalpha.com/news/3296941-rumor-du-jour-impax-labs-mulling-merger-amneal-pharma-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3296941-rumor-du-jour-impax-labs-mulling-merger-amneal-pharma-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296939\" data-ts=\"1506010659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BATRA\" target=\"_blank\">BATRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296939-gabelli-gamco-raise-stake-in-liberty-braves-to-7_74\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gabelli, GAMCO raise stake in Liberty Braves to 7.74%</a></h4><ul>   <li>Liberty Media's Liberty Braves Group Series A (NASDAQ:<a href='https://seekingalpha.com/symbol/BATRA' title='Liberty Braves Series A'>BATRA</a>) is <font color='green'>up 2.2%</font> as Mario Gabelli and GAMCO have <a href=\"https://www.sec.gov/Archives/edgar/data/807249/000080724917000159/batra_02.htm\" target=\"_blank\">boosted their stake</a> in the class to 7.74%.</li>    <li>Gabelli and company have been adding shares in near-daily trades since Aug. 29, when they reported an equity stake of about 6.55%.</li>    <li>In the <a href=\"https://www.sec.gov/Archives/edgar/data/807249/000080724917000159/batra_02.htm\" target=\"_blank\">new filing</a>, GAMCO reports it holds about 792,803 shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296939\" data-linked=\"Gabelli, GAMCO raise stake in Liberty Braves to 7.74%\" data-tweet=\"$BATRA $BATRB $BATRK - Gabelli, GAMCO raise stake in Liberty Braves to 7.74% https://seekingalpha.com/news/3296939-gabelli-gamco-raise-stake-in-liberty-braves-to-7_74?source=tweet\" data-url=\"https://seekingalpha.com/news/3296939-gabelli-gamco-raise-stake-in-liberty-braves-to-7_74\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296934\" data-ts=\"1506009856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIS\" target=\"_blank\">GIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296934-morgan-stanley-adjusts-estimates-on-general-mills-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley adjusts estimates on General Mills lower</a></h4><ul> <li>Morgan Stanley lowers its price target on General Mills (<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a> <font color='red'>-1.2%</font>) to $52 to account for the FQ1 profit miss and new EPS estimates.</li> <li>\"We continue to see risk to the F18 outlook due to ongoing topline uncertainty and resulting volume deleverage/reinvestment needs,\" writes analyst Matthew Grainger and team.</li> <li>MS expects the food company to report 2018 EPS of $3.08 (16.9 PE) and 2019 EPS of 3.20 (16.3 PE).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296526-margin-pressure-general-mills\" target=\"_blank\">Margin pressure at General Mills</a> (Sept. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296934\" data-linked=\"Morgan Stanley adjusts estimates on General Mills lower\" data-tweet=\"$GIS - Morgan Stanley adjusts estimates on General Mills lower https://seekingalpha.com/news/3296934-morgan-stanley-adjusts-estimates-on-general-mills-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3296934-morgan-stanley-adjusts-estimates-on-general-mills-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296931\" data-ts=\"1506009665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296931-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+14%</font>. LTEA <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296931\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NVFY $LBCC $ADOM - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3296931-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296931-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296929\" data-ts=\"1506009418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUVA\" target=\"_blank\">NUVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296929-nuvasive-attractive-entry-point-gabelli\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NuVasive at attractive entry point - Gabelli</a></h4><ul><li>In a note, Gabelli says the time is now to buy NuVasive (<a href='https://seekingalpha.com/symbol/NUVA' title='NuVasive, Inc.'>NUVA</a> <font color='green'>+1.2%</font>) , citing expectations of double-digit earnings growth over the next few years and confidence that it will achieve its long-term goal of a 25% operating margin &#40;BUY&#41;. Shares have lost about a third of their value since late July after its Q2 revenue miss and management shakeup.</li><li>Gabelli also likes Globus Medical &#40;BUY&#41;.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3296929\" data-linked=\"NuVasive at attractive entry point - Gabelli\" data-tweet=\"$NUVA - NuVasive at attractive entry point - Gabelli https://seekingalpha.com/news/3296929-nuvasive-attractive-entry-point-gabelli?source=tweet\" data-url=\"https://seekingalpha.com/news/3296929-nuvasive-attractive-entry-point-gabelli\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296922\" data-ts=\"1506008430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUR\" target=\"_blank\">CUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296922-neuralstem-and-aradigm-spike-equity-offerings-on-way\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neuralstem and Aradigm spike, equity offerings on the way?</a></h4><ul><li>Thinly traded nano caps Neuralstem (<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+17.3%</font>) and Aradigm (<a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+18.7%</font>) are both up on increased volume on no particular news, consistent with recent activity that presaged equity offerings.</li><li>At the end of June, Neuralstem had $11.4M in quick assets and is consuming over $4M per quarter in operations. In late July, it raised ~$6M via an offering of stock and warrants.</li><li>Aradigm's quick asset balance at the end of June was $12.0M, but it made ~$2.0M from operations in Q2. Operations consumed cash of $11.6M in H1. (Both sourced from recent 10-Qs).</li></ul><div class=\"tiny-share-widget\" data-id=\"3296922\" data-linked=\"Neuralstem and Aradigm spike, equity offerings on the way?\" data-tweet=\"$CUR $SNCA $ARDM - Neuralstem and Aradigm spike, equity offerings on the way? https://seekingalpha.com/news/3296922-neuralstem-and-aradigm-spike-equity-offerings-on-way?source=tweet\" data-url=\"https://seekingalpha.com/news/3296922-neuralstem-and-aradigm-spike-equity-offerings-on-way\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296920\" data-ts=\"1506007692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSM\" target=\"_blank\">TSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296920-tsmc-competitor-cries-antitrust-violation-tsmc-and-himax-supplying-iphone-x\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TSMC competitor cries antitrust violation; TSMC and Himax supplying iPhone X?</a></h4><ul><li>GlobalFoundries <a href=\"http://www.reuters.com/article/us-eu-tsmc-globalfoundries-antitrust-exc/exclusive-chipmaker-globalfoundries-asks-eu-to-investigate-bigger-rival-tsmc-source-idUSKCN1BW25D?feedType=RSS&amp;feedName=businessNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FbusinessNews+%28Business+News%29\" target=\"_blank\">asks</a> European antitrust regulators to investigate competitor Taiwan Semiconductor Manufacturing Co (NYSE:<a href='https://seekingalpha.com/symbol/TSM' title='Taiwan Semiconductor Manufacturing Company Ltd.'>TSM</a>) for unfair competition.</li><li>GlobalFoundries says TSMC has unfairly used loyalty and bundled rebates, exclusivity clauses, and penalties to prevent customers from switching to the competition.</li><li>According to IC Insights, TSMC held 58% of the foundry market last year and comes in third in terms of chipmakers behind only Samsung and Intel.</li><li>TSMC spokesperson denial: &ldquo;Any accusation that TSMC threatens or harms customers is absolutely baseless, and we will vigorously defend our hard-earned trust and our most valued reputation.&rdquo;</li><li>GlobalFoundries comment: &ldquo;It is prudent for the regulator to monitor behaviors more closely and GlobalFoundries will naturally support regulatory agencies as they take a closer look at this key industrial sector for Europe and the world.&rdquo;</li><li>European regulators had no comment.</li><li>In other TSMC news, Brightwire <a href=\"https://www.streetinsider.com/Momentum+Movers/TSMC%2C+Himax+%28HIMX%29+to+supply+sensors+for+iPhone+X%2C+source+say+-+Brightwire/13317077.html\" target=\"_blank\">reports</a> that the company and Himax (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) will supply sensors for the iPhone X that an analyst alleges hasn&rsquo;t started final production yet.</li><li>Taiwan Semiconductor shares are&nbsp;<font color='green'>up 0.44%</font>.</li><li>Himax shares are&nbsp;<font color='green'>up 5.83%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296740-raymond-james-apple-begun-final-production-iphone-x\" target=\"_blank\">Raymond James: Apple hasn't begun final production of iPhone X</a> (Sept. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296920\" data-linked=\"TSMC competitor cries antitrust violation; TSMC and Himax supplying iPhone X?\" data-tweet=\"$TSM $TSM $HIMX - TSMC competitor cries antitrust violation; TSMC and Himax supplying iPhone X? https://seekingalpha.com/news/3296920-tsmc-competitor-cries-antitrust-violation-tsmc-and-himax-supplying-iphone-x?source=tweet\" data-url=\"https://seekingalpha.com/news/3296920-tsmc-competitor-cries-antitrust-violation-tsmc-and-himax-supplying-iphone-x\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296919\" data-ts=\"1506007335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCC-OLD\" target=\"_blank\">CCC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296919-calgon-carbon-cut-to-sell-janney-foreign-purchase-poses-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calgon Carbon cut to Sell at Janney, as foreign purchase poses risk</a></h4><ul>     <li>Calgon Carbon (<a href='https://seekingalpha.com/symbol/CCC-OLD' title='Calgon Carbon Corporation'>CCC-OLD</a> <font color='green'>+62.1%</font>) is <a href=\"http://www.marketwatch.com/story/janney-downgrades-calgon-carbon-stock-to-sell-says-kuraray-is-overpaying-for-company-2017-09-21\" target=\"_blank\">downgraded to Sell</a> from Neutral by Janney analysts following the company's proposed <a href=\"https://seekingalpha.com/news/3296831-japan-chemical-maker-kuraray-buy-calgon-carbon-1_3b\" target=\"_blank\">$1.3B takeover</a> by Japan chemical maker Kuraray.</li>     <li>The deal offers a 63% premium, and Janney thinks Kuraray overpaid for the shares and sees additional risk \"given that CCC has a specialty carbon business that supplies the U.S. military with gas masks and other personal protection items, so a foreign buyer could be an issue for U.S. government approval.\"</li>     <li>Janney prefers Mueller Water Products (<a href='https://seekingalpha.com/symbol/MWA' title='Mueller Water Products, Inc.'>MWA</a> <font color='green'>+0.9%</font>) and Rexnord (<a href='https://seekingalpha.com/symbol/RXN' title='Rexnord Corp.'>RXN</a>), which it considers the best value picks in the industrial space.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296919\" data-linked=\"Calgon Carbon cut to Sell at Janney, as foreign purchase poses risk\" data-tweet=\"$CCC-OLD $CCC-OLD $MWA - Calgon Carbon cut to Sell at Janney, as foreign purchase poses risk https://seekingalpha.com/news/3296919-calgon-carbon-cut-to-sell-janney-foreign-purchase-poses-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3296919-calgon-carbon-cut-to-sell-janney-foreign-purchase-poses-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296916\" data-ts=\"1506006979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296916-fda-warns-on-liver-risk-of-intercepts-ocaliva-dosed-incorrectly-shares-slip-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA warns on liver risk of Intercept&#39;s Ocaliva if dosed incorrectly; shares slip 6%</a></h4><ul><li>Intercept Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='red'>-6.3%</font>) is under pressure on the <a href=\"https://www.streetinsider.com/Corporate+News/FDA+Issues+Warning+on+Liver+Injury+from+Intercept+Pharmas+%28ICPT%29+Ocaliva/13317148.html\" target=\"_blank\">news </a>that the FDA has issued a warning that incorrect dosing of PBC med Ocaliva (obeticholic acid) in certain patients with moderate-to-severe decreases in liver function could drastically increase the risk of liver injury and death.</li><li>Patients with moderate-to-severe liver impairment (Child-Pugh B and C) should be started with 5 mg of Ocaliva once per week, rather than <a href=\"https://ocaliva.com/ocaliva_pi.pdf\" target=\"_blank\">once daily </a>for other PBC patients (can be increased to 10 mg twice weekly, if needed). The maximum dose for other PBC patients is 10 mg daily.</li><li>The agency is working with the company to address the safety issue.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294830-intercept-pressure-ocaliva-associated-liver-injury-dosed-frequently-recommended-shares-14\" target=\"_blank\">Intercept under pressure on Ocaliva-associated liver injury when dosed more frequently that recommended; shares down 14% premarket</a> (Sept. 12)</li><li><strong>Update</strong>: Despite efforts from the sell-siders that the selling is overdone, it's not. Shares are down&nbsp;<font color='red'>25%</font>&nbsp;approaching the close.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296916\" data-linked=\"FDA warns on liver risk of Intercept&#39;s Ocaliva if dosed incorrectly; shares slip 6%\" data-tweet=\"$ICPT - FDA warns on liver risk of Intercept&#39;s Ocaliva if dosed incorrectly; shares slip 6% https://seekingalpha.com/news/3296916-fda-warns-on-liver-risk-of-intercepts-ocaliva-dosed-incorrectly-shares-slip-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3296916-fda-warns-on-liver-risk-of-intercepts-ocaliva-dosed-incorrectly-shares-slip-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>125&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296918\" data-ts=\"1506006594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296918-amd-partner-denies-tesla-product-commitment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD partner denies Tesla product commitment</a></h4><ul><li>        Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) partner GlobalFoundries denies CNBC&rsquo;s report yesterday that it has received a Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) commitment for autonomous driving products, via <a href=\"http://www.reuters.com/article/us-tesla-chips/globalfoundries-says-no-commitment-from-tesla-on-chip-deal-idUSKCN1BW259\" target=\"_blank\">Reuters</a>. &nbsp;</li><li>Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) shares had slid on the earlier news and remain&nbsp;<font color='red'>down 3.12%</font>&nbsp;but could now rebound.</li><li>AMD has fallen back and now is only&nbsp;<font color='green'>up 0.21%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296726-cnbc-tesla-working-amd-self-driving-car-chip\" target=\"_blank\">CNBC: Tesla working with AMD on self-driving car chip</a> (Sept. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296918\" data-linked=\"AMD partner denies Tesla product commitment\" data-tweet=\"$AMD $AMD $TSLA - AMD partner denies Tesla product commitment https://seekingalpha.com/news/3296918-amd-partner-denies-tesla-product-commitment?source=tweet\" data-url=\"https://seekingalpha.com/news/3296918-amd-partner-denies-tesla-product-commitment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296886\" data-ts=\"1506006144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296886-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+82%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PAVM' title='PAVmed Inc.'>PAVM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PZRX' title='PhaseRx'>PZRX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296886\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$AKTX $ARDM $SNCA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3296886-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3296886-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296909\" data-ts=\"1506005903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPCN\" target=\"_blank\">LPCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296909-ptab-ruling-bolsters-lipocines-position-in-patent-dispute-clarus-therapeutics-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PTAB ruling bolsters Lipocine&#39;s position in patent dispute with Clarus Therapeutics; shares ahead 2%</a></h4><ul><li>Thinly traded nano cap Lipocine (<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color='green'>+2%</font>) is up in early trading on increased volume after it <a href=\"https://seekingalpha.com/pr/16947369-lipocine-announces-motions-decision-uspto-interference-clarus\" target=\"_blank\">announced </a>a favorable ruling by the USPTO's Patent Trial and Appeal Board &#40;PTAB&#41; regarding its dispute with Clarus Therapeutics.</li><li>The PTAB granted its motion to deny Clarus' previously accorded priority date for its U.S. Patent No. 8,828,428 ('428 patent), establishing a new priority date of April 16, 2014. The PTAB also granted Clarus' motion to deny Lipocine its according priority date for its U.S. Patent Application No. 14/713,692 ('692 Application), setting May 15, 2015 as the date for the application. The decision means that Clarus is the senior party and Lipocine the junior party.</li><li>All other motions were denied. A conference call with the PTAB is set for October 4 to discuss the next steps.</li><li>Lipocine believes the PTAB ruling strengthens its position related to TRT candidate TLANDO (formerly LPCN 1021). About a year ago, a Delaware district court <a href=\"https://globenewswire.com/news-release/2016/10/07/878021/0/en/Lipocine-Wins-Dismissal-of-Patent-Infringement-Lawsuit-Related-to-LPCN-1021.html\" target=\"_blank\">dismissed </a>Clarus' patent infringement lawsuit related to the '428 patent.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296909\" data-linked=\"PTAB ruling bolsters Lipocine&#39;s position in patent dispute with Clarus Therapeutics; shares ahead 2%\" data-tweet=\"$LPCN - PTAB ruling bolsters Lipocine&#39;s position in patent dispute with Clarus Therapeutics; shares ahead 2% https://seekingalpha.com/news/3296909-ptab-ruling-bolsters-lipocines-position-in-patent-dispute-clarus-therapeutics-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3296909-ptab-ruling-bolsters-lipocines-position-in-patent-dispute-clarus-therapeutics-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296913\" data-ts=\"1506005524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERI\" target=\"_blank\">VERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296913-veritoneplus-17-ai-platform-awarded-best-of-ibc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veritone +17% as AI platform awarded best of IBC</a></h4><ul>    <li>Veritone (NASDAQ:<a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a>) has <font color='green'>jumped 17%</font> to a new all-time high the morning after its artificial intelligence solution came away with the \"best of show\" award at IBC.</li>    <li>The product, aiWARE, is a <a href=\"http://www.tvnewscheck.com/article/107052/on-the-ibc-exhibit-floor-quantum\" target=\"_blank\">multi-engine platform</a> that runs in a Quantum StorNext-managed environment.</li>    <li>The result allows customers of the media-software company to leverage the power of cognitive engines in areas including object recognition, optical character recognition and transcription to get new value from existing video and audio without the requirement to move it to the cloud.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296913\" data-linked=\"Veritone +17% as AI platform awarded best of IBC\" data-tweet=\"$VERI - Veritone +17% as AI platform awarded best of IBC https://seekingalpha.com/news/3296913-veritoneplus-17-ai-platform-awarded-best-of-ibc?source=tweet\" data-url=\"https://seekingalpha.com/news/3296913-veritoneplus-17-ai-platform-awarded-best-of-ibc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296912\" data-ts=\"1506005331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDS\" target=\"_blank\">FDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296912-northcoast-research-upgrades-factset-research-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northcoast Research upgrades FactSet Research Systems</a></h4><ul><li>        Northcoast Research <a href=\"https://www.streetinsider.com/Analyst+Comments/Northcoast+Research+Upgrades+FactSet+Research+Systems+%28FDS%29+to+Buy/13316212.html\" target=\"_blank\">upgrades</a> FactSet Research Systems (NYSE:<a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a>) from Neutral to Buy with a $195 price target.</li><li>               Analyst Keith Housum cites the company&rsquo;s revenue base diversification that should have long-term impacts.&nbsp;</li><li>               FactSet Research Systems shares are&nbsp;<font color='green'>up 1.88%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296912\" data-linked=\"Northcoast Research upgrades FactSet Research Systems\" data-tweet=\"$FDS - Northcoast Research upgrades FactSet Research Systems https://seekingalpha.com/news/3296912-northcoast-research-upgrades-factset-research-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3296912-northcoast-research-upgrades-factset-research-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296911\" data-ts=\"1506005165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296911-transoceanminus-6-chevron-ends-rig-contract-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean -6% as Chevron ends rig contract early</a></h4><ul>     <li>Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-5.7%</font>) sinks on news that Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a>) <a href=\"https://seekingalpha.com/pr/16946889-transocean-ltd-receives-early-termination-notice-discoverer-clear-leader\" target=\"_blank\">terminated its contract</a> for an ultra-deepwater drillship, effective in November,&nbsp;prior to its expiration in October 2018.</li>     <li>The <em>Discoverer Clear Leader</em> drillship has been under contract since November 2014 at a $575K dayrate.</li>     <li>RIG says it will be compensated through a ~$148M lump-sum payment in contract termination fees.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296911\" data-linked=\"Transocean -6% as Chevron ends rig contract early\" data-tweet=\"$RIG $RIG $CVX - Transocean -6% as Chevron ends rig contract early https://seekingalpha.com/news/3296911-transoceanminus-6-chevron-ends-rig-contract-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3296911-transoceanminus-6-chevron-ends-rig-contract-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296903\" data-ts=\"1506004229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296903-natural-gas-inventory-builds-slightly-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory builds slightly more than expected</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory: </a>&nbsp;<strong>+97 Bcf</strong> vs. +91 Bcf consensus, +91 Bcf last week.</li><li>Futures&nbsp;<font color='red'>-2.17%</font>&nbsp;to $3.027.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296903\" data-linked=\"Natural gas inventory builds slightly more than expected\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory builds slightly more than expected https://seekingalpha.com/news/3296903-natural-gas-inventory-builds-slightly-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3296903-natural-gas-inventory-builds-slightly-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296899\" data-ts=\"1506003682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296899-mimedx-fights-back-sues-capital-forum-for-libel-shares-continue-slide-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx fights back, sues Capital Forum for libel; shares continue slide, down 9%</a></h4><ul><li>Embattled MiMedx (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='red'>-8.6%</font>) has <a href=\"https://seekingalpha.com/pr/16947698-mimedx-files-lawsuit-capitol-forum\" target=\"_blank\">filed a lawsuit</a> against <a href=\"https://thecapitolforum.com/\" target=\"_blank\">The Capital Forum</a> accusing it of libel, slander, defamation, false light, tortious interference with business relations and violations of the Lanham Act. The company's action stems from an article published on September 7 by investigative news group insinuating that the Department of Veterans Affairs was investigating the company.</li><li>Shares have lost&nbsp;<font color='red'>~</font><font color='red'>35%</font>&nbsp;of their value this month amidst allegations that the company shipped excess product to distributors in order to goose sales, a tactic called channel stuffing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296899\" data-linked=\"MiMedx fights back, sues Capital Forum for libel; shares continue slide, down 9%\" data-tweet=\"$MDXG - MiMedx fights back, sues Capital Forum for libel; shares continue slide, down 9% https://seekingalpha.com/news/3296899-mimedx-fights-back-sues-capital-forum-for-libel-shares-continue-slide-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3296899-mimedx-fights-back-sues-capital-forum-for-libel-shares-continue-slide-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296898\" data-ts=\"1506003198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296898-winnebago-rallies-after-cl-king-gushes-new-models\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Winnebago rallies after CL King gushes about new models</a></h4><ul> <li>Winnebago (<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='green'>+3.7%</font>) trades higher after CL King lifts its price target to a Street high $45.</li> <li>Analyst Scott Stember returned from an indusrty open house with a favorable view of Winnebago's 2018 models.</li> <li>CL King has a Buy rating on Winnebago, one of six bullish views on record from investment firms in comparison to no Sell equivalents ratings.</li><li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296898\" data-linked=\"Winnebago rallies after CL King gushes about new models\" data-tweet=\"$WGO - Winnebago rallies after CL King gushes about new models https://seekingalpha.com/news/3296898-winnebago-rallies-after-cl-king-gushes-new-models?source=tweet\" data-url=\"https://seekingalpha.com/news/3296898-winnebago-rallies-after-cl-king-gushes-new-models\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296897\" data-ts=\"1506002787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296897-eros-internationalminus-12_9-after-monthlong-run\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International -12.9% after monthlong run</a></h4><ul>   <li>Shorts may be back in charge of trading in Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>), <font color='red'>down 12.9%</font> on relatively robust trading so far this morning.</li>    <li>Shares had climbed from $6.85 on Aug. 15 to $15.15 at yesterday's closing. Short percentage of float has climbed to about 52% of float.</li>    <li>The company this hour has dropped a release saying it's sealed a <a href=\"https://seekingalpha.com/pr/16947675-eros-now-announces-content-deal-dharma-productions\" target=\"_blank\">content aggregation deal with Dharma Productions</a>, netting it licensing rights to two of Dharma's latest releases along with 11 catalog films. It has non-exclusive rights for the films in all territories outside India.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296897\" data-linked=\"Eros International -12.9% after monthlong run\" data-tweet=\"$EROS - Eros International -12.9% after monthlong run https://seekingalpha.com/news/3296897-eros-internationalminus-12_9-after-monthlong-run?source=tweet\" data-url=\"https://seekingalpha.com/news/3296897-eros-internationalminus-12_9-after-monthlong-run\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296895\" data-ts=\"1506002601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOLD\" target=\"_blank\">BOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296895-phase-1-2-study-underway-on-audentes-at132-in-rare-inherited-muscle-disorder-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phase 1/2 study underway on Audentes&#39; AT132 in rare inherited muscle disorder; shares up 2%</a></h4><ul><li>Patient dosing has begun in a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03199469?term=aspiro&amp;rank=1\" target=\"_blank\">ASPIRO</a>, assessing Audentes Therapeutics' (<a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics'>BOLD</a> <font color='green'>+2.2%</font>) gene therapy AT132 in patients with <a href=\"https://ghr.nlm.nih.gov/condition/x-linked-myotubular-myopathy#statistics\" target=\"_blank\">X-Linked Myotubular Myopathy</a> &#40;XLMTM&#41;, a rare and serious inherited muscle disorder characterized by extreme muscle weakness, respiratory failure and early death. The study will enroll ~12 patients less than five years old. Preliminary data should be available in Q4.</li><li>According to ClinicalTrials.gov, the estimated primary completion date is March 2019. The estimated study completion date is March 2025.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296895\" data-linked=\"Phase 1/2 study underway on Audentes&#39; AT132 in rare inherited muscle disorder; shares up 2%\" data-tweet=\"$BOLD - Phase 1/2 study underway on Audentes&#39; AT132 in rare inherited muscle disorder; shares up 2% https://seekingalpha.com/news/3296895-phase-1-2-study-underway-on-audentes-at132-in-rare-inherited-muscle-disorder-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3296895-phase-1-2-study-underway-on-audentes-at132-in-rare-inherited-muscle-disorder-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296881\" data-ts=\"1506000632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296881-analysts-weigh-in-on-amds-tesla-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on AMD&#39;s Tesla collaboration</a></h4><ul><li>           Analysts had a <a href=\"https://www.cnbc.com/2017/09/21/wall-street-is-gushing-over-amd-on-its-a-i-chip-relationship-with-tesla.html\" target=\"_blank\">bullish</a> reaction to Tesla working with Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) to build a self-driving car chip but reaffirm the previous ratings and price targets. &nbsp; </li><li>        Rosenblatt Securities Hans Mosesmann reiterates a Buy rating and $22 price target for AMD.</li><li>               Mosesmann writes that the Tesla collaboration validates AMD &ldquo;in a field that nobody was considering as viable&rdquo; and gives the chipmaker its first play in the self-driving market. Mosesmann continues that the deal &ldquo;says that AMD&rsquo;s CPU/GPUs in PC and server markets are the real deal.&rdquo;&nbsp;</li><li>               Jefferies semiconductor analyst Mark Lipacis reiterates his Buy rating and $19 price target for AMD.&nbsp;</li><li>               Lipacis says the Tesla shipments won&rsquo;t have a near-term impact on AMD&rsquo;s bottom line but calls the deal a &ldquo;critical win for AMD&rdquo; that supports the firm&rsquo;s belief the company will benefit from the next big thing in technology.&nbsp;</li><li>               Lipacis also comments on Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>), which was bumped to the side in favor of AMD, saying that near-term headline risks aren&rsquo;t favorable but he doesn&rsquo;t see a long-term risk.&nbsp;</li><li>               AMD shares are&nbsp;<font color='green'>up 1.89%</font>&nbsp;premarket.&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='red'>down 2.3%</font>&nbsp;premarket.&nbsp;&nbsp;  </li><li>Previously: <a href=\"https://seekingalpha.com/news/3296726-cnbc-tesla-working-amd-self-driving-car-chip\" target=\"_blank\">CNBC: Tesla working with AMD on self-driving car chip</a> (Sept. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296881\" data-linked=\"Analysts weigh in on AMD&#39;s Tesla collaboration\" data-tweet=\"$AMD $AMD $NVDA - Analysts weigh in on AMD&#39;s Tesla collaboration https://seekingalpha.com/news/3296881-analysts-weigh-in-on-amds-tesla-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3296881-analysts-weigh-in-on-amds-tesla-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>98&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296880\" data-ts=\"1506000545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHL\" target=\"_blank\">SCHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296880-scholasticminus-5-q1-earnings-miss-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scholastic -5% as Q1 earnings miss consensus</a></h4><ul>   <li>Scholastic (NASDAQ:<a href='https://seekingalpha.com/symbol/SCHL' title='Scholastic Corporation'>SCHL</a>) is <font color='red'>off 5%</font> premarket after posting <a href=\"https://seekingalpha.com/news/3296817-scholastic-reports-q1-results\" target=\"_blank\">fiscal Q1 earnings</a> that missed on top and bottom lines as revenues fell by a third in a tough comp vs. a 2016 that included a <i>Harry Potter</i> book.</li>    <li>The company lost $1.81/share (it usually loses money in Q1 when schools aren't in session), but it says it expects to meet its revenue plan in the Education unit for the fiscal year.</li>    <li>Revenue breakout: Children's Book Publishing and Distribution, $66.8M (down 52%); Education, $45M (down 18%); International, $77.4M (down 14%).</li>    <li>Free cash use was $131M, in line with company expectations. Cash and equivalents exceeded debt by $299.9M.</li>    <li>It's affirmed its full-year outlook for revenues of $1.65B-$1.7B (vs. consensus for $1.68B) and EPS of $1.20-$1.30 (vs. expectations for $1.24).</li>    <li><a href=\"https://seekingalpha.com/pr/16947252-scholastic-reports-fiscal-2018-first-quarter-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296880\" data-linked=\"Scholastic -5% as Q1 earnings miss consensus\" data-tweet=\"$SCHL - Scholastic -5% as Q1 earnings miss consensus https://seekingalpha.com/news/3296880-scholasticminus-5-q1-earnings-miss-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3296880-scholasticminus-5-q1-earnings-miss-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296879\" data-ts=\"1506000365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRB\" target=\"_blank\">CLRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296879-cellectar-bio-teams-up-onconova-to-develop-pdcs-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectar Bio teams up with Onconova to develop PDCs; shares ahead 4% premarket</a></h4><ul><li>Thinly traded nano cap Cellectar Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume in response to its strategic <a href=\"https://seekingalpha.com/pr/16947462-cellectar-biosciences-enters-strategic-collaboration-onconova-therapeutics-develop-new\" target=\"_blank\">collaboration </a>with Onconova Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a>) to develop new phospholipid drug conjugates (PDCs) combining Cellectar's phospholipid ether delivery platform with selected compound/payloads from Onconova's early-stage pipeline.</li><li>Under the terms of the partnership, Onconova will provide several compounds, including some from the family of molecules containing briciclib, that Cellectar will link to its PDC platform. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296879\" data-linked=\"Cellectar Bio teams up with Onconova to develop PDCs; shares ahead 4% premarket\" data-tweet=\"$CLRB $CLRB $ONTX - Cellectar Bio teams up with Onconova to develop PDCs; shares ahead 4% premarket https://seekingalpha.com/news/3296879-cellectar-bio-teams-up-onconova-to-develop-pdcs-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296879-cellectar-bio-teams-up-onconova-to-develop-pdcs-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296875\" data-ts=\"1506000192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296875-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/CCC-OLD' title='Calgon Carbon Corporation'>CCC-OLD</a> <font color='green'>+62%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3296831-japan-chemical-maker-kuraray-buy-calgon-carbon-1_3b\" target=\"_blank\">acquired</a> by Kuraray.</li><li>ITUS <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16947309-itus-provides-update-cancer-detection-technology-new-car-t-initiative-ovarian-cancer\" target=\"_blank\">update</a> on&nbsp;cancer detection technology new cart initiative ovarian cancer.</li><li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+9%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3296822-fda-oks-expanded-use-biocrysts-flu-med-rapivab-shares-ahead-8-percent-premarket\" target=\"_blank\">OKs</a> expanded use of BioCryst's flu med Rapivab.</li><li><a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3296859-eldorado-gold-says-dispute-talks-greece-can-bear-fruit\" target=\"_blank\">constructive</a> dialogue greek government&nbsp;for the development Hellas Gold S.A.'s,&nbsp;Kassandra Mine&nbsp;assets in Halkidiki.</li><li><a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+6%</font>&nbsp;on $2.5B stock <a href=\"https://seekingalpha.com/news/3296743-anadarko-petroleum-launches-2_5b-stock-buyback\" target=\"_blank\">buyback</a>.</li><li><a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296827-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li><li><a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corp'>ABUS</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296875\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CCC-OLD $ANIX $TEUM - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3296875-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3296875-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296866\" data-ts=\"1505999214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296866-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3296866\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CAPR - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3296866-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3296866-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296856\" data-ts=\"1505997858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPRE\" target=\"_blank\">TPRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296856-third-point-reinsurance-jumps-after-index-inclusion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Third Point Reinsurance jumps after index inclusion</a></h4><ul>     <li>Third Point Reinsurance (NYSE:<a href='https://seekingalpha.com/symbol/TPRE' title='Third Point Reinsurance'>TPRE</a>) will replace Sanderson Farms in the S&amp;P SmallCap 600 Index prior to the open on September 26.</li>     <li>Shares of Third Point are&nbsp;<font color='green'>up 5.56%</font>&nbsp;in premarket trading to $15.20 (52-week high).</li>     <li><a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/587349_3pointsandfarm4cabela.pdf?force_download=true\" target=\"_blank\">S&amp;P press release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3296856\" data-linked=\"Third Point Reinsurance jumps after index inclusion\" data-tweet=\"$TPRE - Third Point Reinsurance jumps after index inclusion https://seekingalpha.com/news/3296856-third-point-reinsurance-jumps-after-index-inclusion?source=tweet\" data-url=\"https://seekingalpha.com/news/3296856-third-point-reinsurance-jumps-after-index-inclusion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296846\" data-ts=\"1505997132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABMD\" target=\"_blank\">ABMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296846-abiomed-receives-fda-pma-approval-for-impella-rp-for-right-heart-failure-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abiomed receives FDA PMA approval for Impella RP for right heart failure; shares ahead 2% premarket</a></h4><ul> <li>Abiomed (NASDAQ:<a href='https://seekingalpha.com/symbol/ABMD' title='ABIOMED, Inc.'>ABMD</a>) <a href=\"http://investors.abiomed.com/releasedetail.cfm?ReleaseID=1041176\" target=\"_blank\">announces</a> that it has received FDA premarket approval &#40;PMA&#41; for the <a href=\"http://www.abiomed.com/impella/impella-rp\" target=\"_blank\">Impella RP&nbsp;heart pump</a>&nbsp;for providing temporary right ventricular support for up to 14 days in patients with a minimum body surface area (at least 1.5 m2) who develop right heart failure or decompensation following left ventricular assist device implantation, heart attack, heart transplant or open-heart surgery.</li><li>The company says the Impella is the only FDA-approved percutaneous temporary ventricular support device for right heart failure.</li>       <li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3296846\" data-linked=\"Abiomed receives FDA PMA approval for Impella RP for right heart failure; shares ahead 2% premarket\" data-tweet=\"$ABMD - Abiomed receives FDA PMA approval for Impella RP for right heart failure; shares ahead 2% premarket https://seekingalpha.com/news/3296846-abiomed-receives-fda-pma-approval-for-impella-rp-for-right-heart-failure-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3296846-abiomed-receives-fda-pma-approval-for-impella-rp-for-right-heart-failure-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296834\" data-ts=\"1505995373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296834-akari-to-advance-coversin-phase-3-for-pnh-in-q1-2018-shares-up-90\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari to advance Coversin into Phase 3 for PNH in Q1 2018; shares up 90%</a></h4><ul><li>Based on feedback from an End-of-Phase 2 meeting with the FDA, Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a>) will <a href=\"https://seekingalpha.com/pr/16947230-akari-therapeutics-announces-regulatory-progress-following-fda-meeting\" target=\"_blank\">advance </a>lead candidate Coversin into Phase 3 development for the treatment of Paroxysmal Nocturnal Hemoglobinuria &#40;PNH&#41; in Q1 2018. The PNH indication has Fast Track status in the U.S.</li><li>The company plans to conduct two studies: CAPSTONE, in na&iuml;ve PNH patients where Alexion's Soliris (eculizumab) is not the standard of care and ASSET, in PNH patients on eculizumab therapy who will be switched to Coversin.</li><li>Coversin is a second-generation complement inhibitor.</li><li><strong>Update</strong>: Shares are up<font color='green'> 90%</font>&nbsp;in early trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296834\" data-linked=\"Akari to advance Coversin into Phase 3 for PNH in Q1 2018; shares up 90%\" data-tweet=\"$AKTX - Akari to advance Coversin into Phase 3 for PNH in Q1 2018; shares up 90% https://seekingalpha.com/news/3296834-akari-to-advance-coversin-phase-3-for-pnh-in-q1-2018-shares-up-90?source=tweet\" data-url=\"https://seekingalpha.com/news/3296834-akari-to-advance-coversin-phase-3-for-pnh-in-q1-2018-shares-up-90\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296837\" data-ts=\"1505995357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLNG\" target=\"_blank\">GLNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296837-golar-lng-names-worleyparsons-exec-ross-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golar LNG names WorleyParsons exec Ross as new CEO</a></h4><ul>     <li>Golar LNG&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/GLNG' title='Golar LNG Limited'>GLNG</a>) names Iain Ross as its <a href=\"https://seekingalpha.com/pr/16947116-organisational-changes-golar\" target=\"_blank\">new CEO</a>, effective immediately, succeeding Oscar Spieler.</li><li>Ross joins GLNG from project delivery company WorleyParsons (<a href='https://seekingalpha.com/symbol/WYGPF' title='Worley Parsons Ltd.'>OTCPK:WYGPF</a>), where he held executive positions since 2002.</li>     <li>Spieler was appointed as CEO last year after previously leading the company during 2009-11, and has been in charge of the company&rsquo;s FLNG Hilli Episeyo project; he will remain with GLNG as executive advisor.</li><li>GLNG <font color='red'>-3.1%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296837\" data-linked=\"Golar LNG names WorleyParsons exec Ross as new CEO\" data-tweet=\"$GLNG $GLNG $WYGPF - Golar LNG names WorleyParsons exec Ross as new CEO https://seekingalpha.com/news/3296837-golar-lng-names-worleyparsons-exec-ross-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3296837-golar-lng-names-worleyparsons-exec-ross-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296833\" data-ts=\"1505994843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLRN\" target=\"_blank\">XLRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296833-acceleron-prices-5_4m-shares-of-common-stock-offering-37-shares-off-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acceleron prices 5.4M shares of common stock offering at $37; shares off 1% premarket</a></h4><ul> <li>Acceleron Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a>) <a href=\"https://seekingalpha.com/pr/16947053-acceleron-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a> a public       offering of 5.4M shares of common stock at a price of       $37.00 per share for net proceeds of ~$187.6M.</li><li>Underwriters over-allotment is an additional 810,810 shares.</li>     <li>Net proceeds will be used for clinical trials, capital expenditures, working capital and general corporate purposes.</li>     <li>Closing date is September 25.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on average volume. Yesterday's close was $37.73.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3296833\" data-linked=\"Acceleron prices 5.4M shares of common stock offering at $37; shares off 1% premarket\" data-tweet=\"$XLRN - Acceleron prices 5.4M shares of common stock offering at $37; shares off 1% premarket https://seekingalpha.com/news/3296833-acceleron-prices-5_4m-shares-of-common-stock-offering-37-shares-off-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296833-acceleron-prices-5_4m-shares-of-common-stock-offering-37-shares-off-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296829\" data-ts=\"1505994513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296829-amicus-therapeutics-atb200-at2221-orphan-drug-in-u-s-for-pompe-disease-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus Therapeutics&#39; ATB200/AT2221 an Orphan Drug in U.S. for Pompe disease; shares ahead 2% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16947286-u-s-fda-grants-orphan-drug-designation-atb200-at2221-pompe-disease\" target=\"_blank\">designates </a>Amicus Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) ATB200/AT2221 an Orphan Drug for the treatment of Pompe disease, an inherited lysosomal storage disorder caused by the deficiency in an enzyme called acid alpha-glucosidase.</li><li><a href=\"http://amicusrx.com/pompe_disease.php\" target=\"_blank\">ATB200/AT2221</a>&nbsp;is a new treatment paradigm consisting of ATB200, a recombinant acid alpha-glucosidase with enhanced uptake characteristics and AT2221, a pharmacological chaperone.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296829\" data-linked=\"Amicus Therapeutics&#39; ATB200/AT2221 an Orphan Drug in U.S. for Pompe disease; shares ahead 2% premarket\" data-tweet=\"$FOLD - Amicus Therapeutics&#39; ATB200/AT2221 an Orphan Drug in U.S. for Pompe disease; shares ahead 2% premarket https://seekingalpha.com/news/3296829-amicus-therapeutics-atb200-at2221-orphan-drug-in-u-s-for-pompe-disease-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3296829-amicus-therapeutics-atb200-at2221-orphan-drug-in-u-s-for-pompe-disease-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296831\" data-ts=\"1505994305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCC-OLD\" target=\"_blank\">CCC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296831-japan-chemical-maker-kuraray-to-buy-calgon-carbon-for-1_3b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Japan chemical maker Kuraray to buy Calgon Carbon for $1.3B</a></h4><ul>     <li>Calgon Carbon (NYSE:<a href='https://seekingalpha.com/symbol/CCC-OLD' title='Calgon Carbon Corporation'>CCC-OLD</a>) <font color='green'>+62.1%</font> premarket after <a href=\"http://www.calgoncarbon.com/media/press-releases/2017-21-09/calgon-carbon-corporation-announces-agreement-acquired-kuraray/\" target=\"_blank\">agreeing to be acquired</a> by Japanese chemical manufacturer Kuraray for $21.50/share, a 62.9% premium to CCC's closing price yesterday.</li><li>Including debt, the deal value totals $1.3B.</li><li>CCC will become a wholly owned subsidiary of Kuraray, which says it plans to leverage CCC&rsquo;s global presence to <a href=\"http://www.reuters.com/article/us-global-oil/oil-prices-slip-ahead-of-key-opec-meeting-idUSKCN1BW07Z\" target=\"_blank\">expand</a> its carbon materials business in areas including energy and water.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3296831\" data-linked=\"Japan chemical maker Kuraray to buy Calgon Carbon for $1.3B\" data-tweet=\"$CCC-OLD - Japan chemical maker Kuraray to buy Calgon Carbon for $1.3B https://seekingalpha.com/news/3296831-japan-chemical-maker-kuraray-to-buy-calgon-carbon-for-1_3b?source=tweet\" data-url=\"https://seekingalpha.com/news/3296831-japan-chemical-maker-kuraray-to-buy-calgon-carbon-for-1_3b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296827\" data-ts=\"1505993791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296827-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>) initiated with Buy rating and $51 (78% upside) price target by Needham citing the promise of lead drug GBT440 in sickle cell disease.</li><li>Patterson Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a>) initiated with Equal Weight rating by Morgan Stanley.</li><li>Henry Schein (NASDAQ:<a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a>) initiated with Equal Weight rating by Morgan Stanley.</li><li>Dr. Reddy's Laboratories (NYSE:<a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a>) upgraded to Overweight by Morgan Stanley. Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li><li>Catalent (NYSE:<a href='https://seekingalpha.com/symbol/CTLT' title='Catalent'>CTLT</a>) upgraded to Overweight by Morgan Stanley.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) downgraded to Market Perform by Raymond James.</li><li>Kindred Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a>) price target lowered to $7.50 (34% upside) from $9.00 by &nbsp;RBC Capital Markets citing the financial impact of recent hurricanes.</li><li>Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma'>NTEC</a>) price target raised to $15 (76% upside) from $10 by Oppenheimer citing operational progress by new management and upside from Accordion Pill platform.</li><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) price target raised to $125 (10% upside) by Needham based on positive late-stage results for TTR amyloidosis med patisiran.</li><li>Exact Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/EXAS' title='EXACT Sciences Corporation'>EXAS</a>) price target raised to $50 from $45 by Leerink.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) price target cut to $20 (17% upside) from $28 by Bernstein.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3296827\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$GBT $GBT $PDCO - Premarket analyst action - healthcare https://seekingalpha.com/news/3296827-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3296827-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296826\" data-ts=\"1505993699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRH\" target=\"_blank\">CRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296826-crh-buys-ash-grove-cement-for-3_5b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRH buys Ash Grove Cement for $3.5B</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CRH' title='CRH, plc'>CRH</a> <font color='green'>+2%</font> premarket after <a href=\"http://www.crh.com/media/news-events/press-releases/2017/2017/09/21/crh-agrees-us$3.5bn-acquisition-of-ash-grove-cement\" target=\"_blank\">agreeing to acquire</a> Kansas-based cement manufacturer Ash Grove Cement (<a href='https://seekingalpha.com/symbol/ASHG' title='Ash Grove Cement Co.'>OTCPK:ASHG</a>) for $3.5B, expanding the Irish company's presence in North America.</li>     <li>ASHG operates eight cement plants across eight U.S. states, combined with ready-mixed concrete, aggregates and associated logistics assets in the U.S. midwest.</li><li>CRH, which sold its&nbsp;interior building-products division to Beacon Roofing <a href=\"https://seekingalpha.com/news/3291428-crh-sells-u-s-distribution-arm-beacon\" target=\"_blank\">last month</a>, <a href=\"https://www.bloomberg.com/news/articles/2017-09-21/crh-to-buy-ash-grove-with-3-5-billion-enterprise-value\" target=\"_blank\">saw potential</a> for further acquisitions after the deal left it with more cash in hand, Bloomberg reports.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296826\" data-linked=\"CRH buys Ash Grove Cement for $3.5B\" data-tweet=\"$CRH $CRH $ASHG - CRH buys Ash Grove Cement for $3.5B https://seekingalpha.com/news/3296826-crh-buys-ash-grove-cement-for-3_5b?source=tweet\" data-url=\"https://seekingalpha.com/news/3296826-crh-buys-ash-grove-cement-for-3_5b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296822\" data-ts=\"1505992653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296822-fda-oks-expanded-use-of-biocrysts-flu-med-rapivab-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs expanded use of BioCryst&#39;s flu med Rapivab; shares ahead 8% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16947169-biocryst-s-rapivab-peramivir-injection-receives-fda-approval-pediatric-indication\" target=\"_blank\">approves </a>the use of BioCryst Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) RAPIVAB (peramivir injection) to treat acute uncomplicated influenza in pediatric patients at least two years old who have been symptomatic for no more than two days.</li><li>The intravenous viral neuraminidase inhibitor was first approved in the U.S. in December 2014 for patients at least 18 years old.</li><li>Shares are up<font color='green'> 8%</font>&nbsp;premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296822\" data-linked=\"FDA OKs expanded use of BioCryst&#39;s flu med Rapivab; shares ahead 8% premarket\" data-tweet=\"$BCRX - FDA OKs expanded use of BioCryst&#39;s flu med Rapivab; shares ahead 8% premarket https://seekingalpha.com/news/3296822-fda-oks-expanded-use-of-biocrysts-flu-med-rapivab-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296822-fda-oks-expanded-use-of-biocrysts-flu-med-rapivab-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":53,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}